Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress detailing the MAIA-ovarian study of its anti-PVRIG antibody COM701. The randomized adaptive platform trial is evaluating COM701 as a maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer, where no standard of care currently exists.
Key figures
- Drug Name
- COM701
- Trial id
- NCT06888921
- Poster number
- 170
- Data readout date
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.